CHT101

CHT101 · Tianjin Medical University Cancer Institute and Hospital

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for CHT101, covering 2024-12-12 to 2026-04-07. Get the full timeline:

Most recent: Clinical Trial Update: Universal Anti-CD70 CAR-T (CHT101) Cell Therapy for Relapsed Refractory Systemic Lupus Erythematosus [EARLY_Phase 1]

See pricing